Efficacy of Abrocitinib and Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Using Treat-to-Target Goals Recommended by Experts in China
Greater proportions of patients attained the 1-year T2T improvements proposed by Zhao and Gao with abrocitinib 200 mg than with dupilumab. Early achievement of 1-year targets in many patients treated with abrocitinib suggest that target domains may necessitate re-evaluation.
Authors
- Melissa Watkins (ORCID: https://orcid.org/0009-0002-8547-6624)
- S. Pan
- Yangfeng Yangfeng Ding
- Zuotao Zhao
- Xing-Hua Gao
- Claire Feeney
- Stephan Weidinger
- Hong Liu
- Meena Arumugam
- Shiqi Li
- Xin Luo
Publication Details
- Journal
- International Archives of Allergy and Immunology
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1159/000550965
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00